Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | WH Wilson, JF Gerecitano, A Goy, S de Vos, VP Kenkre, PM Barr, KA Blum, AR Shustov, RH Advani, J Lih, M Williams, R Schmitz, Y Yang, S Pittaluga, G Wright, LA Kunkel, J McGreivy, S Balasubramanian, M Cheng, D Moussa, JJ Buggy, LM Staudt | ||||||||||||
Title | The Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), Has Preferential Activity in the ABC Subtype of Relapsed/Refractory De Novo Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results of a Multicenter, Open-Label, Phase 2 Study | ||||||||||||
|
|||||||||||||
URL | http://www.bloodjournal.org/content/120/21/686?sso-checked=true | ||||||||||||
Abstract Text | Blood 2012, 120 (21): 686 |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|